WALK

Amey Desai is Season 3's most personally medically-rooted deep-tech founder a biomedical engineer whose parents are both medical professionals (his father Dr. Devendra Desai heads WALK's research team), giving him the specific intersection of clinical understanding (what Parkinson's patients actually experience daily) and engineering capability (how to build a device that addresses those specific challenges) that most medtech founders spend years acquiring separately. Amey founded Lifespark Technologies in 2018 at IIT Bombay with a broader mission: developing AI-powered care solutions for chronic neurological conditions including Parkinson's Disease, Stroke, and Spinal Cord Injury. WALK was the first product from this platform, targeting the most immediately life-threatening symptom of Parkinson's: Freezing of Gait, where patients' feet suddenly feel glued to the ground mid-stride, causing falls that lead to serious injuries and death.

WALK is a wearable mobility aid that addresses one of Parkinson's Disease's most dangerous symptoms: Freezing of Gait. Over 10 lakh Indians suffer from Parkinson's, with 90% of patients over 60 years of age. Freezing of Gait is a brief episodic absence of forward progress of the feet despite the intention to walk, leading to loss of balance, serious falls, injuries, and in some cases, death. WALK uses neuromodulation technology to provide targeted haptic stimulation to the patient's leg muscles, overriding the freezing signal and enabling coordinated movement. The device's onboard sensors continuously collect gait movement data, creating a comprehensive patient profile that healthcare professionals can monitor remotely through the PATHFINDER platform, enabling adaptive therapy that adjusts stimulation parameters based on the individual patient's movement patterns.

Amount Asked: ₹50 lakhs Equity Offered: 1.5% Implied Pre-Money Valuation: ₹33.33 crore

Amey walked into Season 3 Episode 14 as Season 3's most mission-driven medical device founder opening with the human reality of Parkinson's Disease: 10 lakh Indians suffering, 90% over 60 years old, feet freezing mid-stride, falls causing life-threatening injuries, and no existing wearable solution anywhere in the world. The WALK device demonstration was Season 3 Episode 14's most emotionally powerful product showcase showing how the wearable leg device detected the onset of freezing and provided immediate haptic stimulation that enabled the patient to resume walking. The combination of a deeply personal founding motivation (medical professional parents, daily exposure to neurological patients) and a genuinely world-first technology created the pitch's emotional and commercial resonance simultaneously.

Namita Thapar was the only Shark to exit citing lack of trust in the product's clinical data and insufficient evidence from only 150 pilot patients. Amit Jain gave the first offer at ₹50 lakhs for 5% equity, then revised to 3.5% in the competitive bidding. He appreciated Amey's passion and the world-first positioning but was ultimately outbid by the Aman-Anupam coalition. Vineeta Singh stated she never invests in pre-revenue companies but made an exception for WALK. She matched each competing offer progressively from 5% to 4% before the founder chose the Aman-Anupam duo. Aman Gupta was impressed by Amey's passion and the technology's uniqueness. He joined Anupam to make a combined offer, matching every competing bid round for round from 5% to 4% to 3.5%, and ultimately won the deal at the founder's counter of 2.3%. Anupam Mittal questioned whether similar solutions existed globally and was satisfied by Amey's explanation of WALK's unique neuromodulation approach. He joined Aman for the winning coalition, valuing the social impact alongside the commercial potential.

Season 3's most competitively escalating medical device negotiation unfolded across six rounds. Amit opened at ₹50L for 5%. Vineeta matched at 5%. Aman-Anupam matched at 5%. Vineeta revised to 4%. Aman-Anupam matched at 4%. Amit revised to 3.5%. Aman-Anupam matched at 3.5%. The founder then countered all competing parties at ₹50 lakhs for 2.3% equity (₹21.74 crore valuation). Amit and the Aman-Anupam duo both wanted to accept the 2.3% counter. The founder chose Aman and Anupam, and they shook hands.

Amey Desai accepted Aman Gupta and Anupam Mittal's offer of ₹50 lakhs for 2.3% equity at ₹21.74 crore valuation. The founder's negotiation from 1.5% ask through competitive bidding that drove all Sharks from 5% down to 2.3% was Season 3 Episode 14's most effectively executed founder-led valuation negotiation, leveraging three-way Shark competition to achieve terms very close to his original equity ask.

WALK gained substantial traction and visibility after its appearance on Shark Tank India, boosting its market presence and driving further growth. Lifespark Technologies continues building from its IIT Bombay incubation base. The company's post-Shark Tank trajectory includes the Instagram following surging to 1.4 million followers, expanded clinical awareness nationally, and the WALK device moving from pilot phase (150 patients) toward commercial distribution targeting 700 units in FY24-25. The PATHFINDER platform which remotely monitors patients' gait data and enables healthcare professionals to adjust therapy parameters without in-person visits represents the company's most commercially scalable digital health asset beyond the physical device. As India's elderly population grows and neurological disease prevalence increases, the combination of a wearable device (WALK) and a remote monitoring platform (PATHFINDER) creates an integrated care solution that hospitals and clinics can adopt as a standard Parkinson's management protocol.